JP2002529066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002529066A5 JP2002529066A5 JP2000581045A JP2000581045A JP2002529066A5 JP 2002529066 A5 JP2002529066 A5 JP 2002529066A5 JP 2000581045 A JP2000581045 A JP 2000581045A JP 2000581045 A JP2000581045 A JP 2000581045A JP 2002529066 A5 JP2002529066 A5 JP 2002529066A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polynucleotide
- ctgf
- guc
- cag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 description 34
- 102000040430 polynucleotide Human genes 0.000 description 34
- 239000002157 polynucleotide Substances 0.000 description 34
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 27
- 102100031168 CCN family member 2 Human genes 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 150000007523 nucleic acids Chemical group 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010039580 Scar Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000009787 cardiac fibrosis Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 210000001608 connective tissue cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 201000002793 renal fibrosis Diseases 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/187,478 US6348329B1 (en) | 1998-11-06 | 1998-11-06 | Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use |
| US09/187,478 | 1998-11-06 | ||
| US09/292,036 | 1999-04-14 | ||
| US09/292,036 US6358741B1 (en) | 1998-11-06 | 1999-04-14 | Connective tissue growth factor (CTGF) and methods of use |
| PCT/US1999/026189 WO2000027868A2 (en) | 1998-11-06 | 1999-11-05 | Connective tissue growth factor (ctgf) and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002529066A JP2002529066A (ja) | 2002-09-10 |
| JP2002529066A5 true JP2002529066A5 (enExample) | 2007-01-11 |
| JP4698837B2 JP4698837B2 (ja) | 2011-06-08 |
Family
ID=22689164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000581045A Expired - Lifetime JP4698837B2 (ja) | 1998-11-06 | 1999-11-05 | 結合組織成長因子（ｃｔｇｆ）および使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US6348329B1 (enExample) |
| JP (1) | JP4698837B2 (enExample) |
| KR (1) | KR20010102943A (enExample) |
| HK (1) | HK1039342A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562618B1 (en) * | 1997-12-25 | 2003-05-13 | Japan Tobacco, Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| AU775391B2 (en) * | 1998-12-14 | 2004-07-29 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| US7115390B1 (en) * | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| US6444657B1 (en) * | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
| US6965025B2 (en) * | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| EP1616568A3 (en) | 2002-04-30 | 2006-06-21 | Alcon, Inc | GSK-3 inhibitors and CDK inhibitors as anti-glaucoma agents |
| RU2332213C2 (ru) | 2002-04-30 | 2008-08-27 | Алькон, Инк. | Агенты, которые регулируют, ингибируют или модулируют активность и/или экспрессию факторов роста соединительной ткани (фрст), в качестве уникальных средств для снижения внутриглазного давления и лечения глаукоматозных ретинопатий/оптических невропатий |
| AU2003240556A1 (en) * | 2002-06-04 | 2003-12-19 | Metabolex, Inc. | Methods of diagnosing and treating diabetes and insulin resistance |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| US20050153395A1 (en) * | 2003-09-29 | 2005-07-14 | Children's Hospital Inc. | Unique integrin binding site in connective tissue growth factor (CTGF) |
| DE602005008013D1 (de) * | 2004-02-11 | 2008-08-21 | Fibrogen Inc | Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie |
| TWI386225B (zh) * | 2004-12-23 | 2013-02-21 | Alcon Inc | 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術 |
| WO2006102333A2 (en) * | 2005-03-21 | 2006-09-28 | Alcon Manufacturing, Ltd. | Ophthalmic use of agents which inhibit connective tissue growth factor binding and signalling via the trka/p75ntr receptor complex |
| US20100034892A1 (en) | 2006-08-30 | 2010-02-11 | The Trustees Of Columbia University In The City Of New York | Treatment for bone formation disorders by growth factor delivery |
| KR101877698B1 (ko) | 2008-08-25 | 2018-07-12 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도 |
| US8946172B2 (en) * | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| CN102666587A (zh) | 2009-07-02 | 2012-09-12 | 菲布罗根有限公司 | 用于治疗肌营养不良的方法 |
| US20120244169A1 (en) | 2009-11-06 | 2012-09-27 | Fibrogen, Inc. | Treatment for Radiation-Induced Disorders |
| US20140134181A1 (en) | 2010-11-05 | 2014-05-15 | Kenneth E. Lipson | Treatment Method For Lung Remodeling Diseases |
| EP2670411B1 (en) | 2011-02-02 | 2019-04-10 | Excaliard Pharmaceuticals, Inc. | Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars |
| US8802839B2 (en) | 2011-07-15 | 2014-08-12 | Fibrogen, Inc. | Connective tissue growth factor antisense oligonucleotides |
| WO2017100193A1 (en) | 2015-12-10 | 2017-06-15 | Fibrogen, Inc. | Methods for treatment of motor neuron diseases |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5094941A (en) | 1987-12-31 | 1992-03-10 | Zymogenetics, Inc. | Monoclonal antibodies to PDGF |
| US5147294A (en) | 1990-10-01 | 1992-09-15 | Trustees Of Boston University | Therapeutic method for reducing chronic pain in a living subject |
| WO1992011364A1 (en) | 1990-12-21 | 1992-07-09 | Creative Biomolecules, Inc. | Biosynthetic pdgf antagonists |
| US5770209A (en) | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
| US5408040A (en) | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
| US5596090A (en) * | 1992-07-24 | 1997-01-21 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human VCAM-1 RNA |
| US5916756A (en) | 1993-12-14 | 1999-06-29 | University Of South Florida | Assay of connective tissue growth factor for detection of cell proliferative disorders |
| US6562618B1 (en) * | 1997-12-25 | 2003-05-13 | Japan Tobacco, Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| JP4537507B2 (ja) * | 1997-12-25 | 2010-09-01 | アムジェン インコーポレイテッド | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
-
1998
- 1998-11-06 US US09/187,478 patent/US6348329B1/en not_active Expired - Lifetime
-
1999
- 1999-04-14 US US09/292,036 patent/US6358741B1/en not_active Expired - Lifetime
- 1999-11-05 JP JP2000581045A patent/JP4698837B2/ja not_active Expired - Lifetime
- 1999-11-05 HK HK02100878.5A patent/HK1039342A1/zh unknown
- 1999-11-05 KR KR1020017005703A patent/KR20010102943A/ko not_active Withdrawn
-
2002
- 2002-02-19 US US10/080,173 patent/US20020115156A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002529066A5 (enExample) | ||
| Rokeach et al. | Molecular cloning of a cDNA encoding the human Sm-D autoantigen. | |
| JP2023120412A (ja) | 非組み込みウイルス送達系およびその関連方法 | |
| EP2966170A1 (en) | HBV inactivation | |
| JP2008525033A5 (enExample) | ||
| JP2025114562A (ja) | 非組み込みウイルス送達システムおよびその使用の方法 | |
| JPH06500012A (ja) | ウィルス（ｈｉｖ）増殖抑制 | |
| JP2001503277A (ja) | ウイルス変種およびその検出方法 | |
| CA3134944A1 (en) | Engineered mrna sequences and uses thereof | |
| JP2008533988A5 (enExample) | ||
| WO2020165907A9 (en) | Spt5 inhibitors and uses thereof | |
| US6338949B1 (en) | Nucleic acids encoding receptor recognition factor stat4 and methods of use thereof | |
| JP2024116343A (ja) | ヘパピティスｂウイルス複製およびヘパピティスｂウイルス表面抗原分泌の抑制方法 | |
| CN109929865B (zh) | 基于gal4-uas系统的crispr辅助反式增强子激活基因表达的方法及其应用 | |
| JP7754829B2 (ja) | インビトロトランスクリプトｍｒｎａ及びこれを含有する薬学組成物 | |
| JPS62270599A (ja) | インターフェロンにより誘導されるヒト蛋白質に対するモノクローナル抗体 | |
| WO2025045078A1 (zh) | 一种用于调控rna甲基化修饰的编辑系统及其应用 | |
| US20070111231A1 (en) | Detection of mutations in a gene associated with resistance to viral infection, OAS2 and OAS3 | |
| JP2003512028A5 (enExample) | ||
| WO2022217072A1 (en) | Rapid drug-screening platform using crispr gain-of-function approach and pseudoviral selection assay to identify clinical biomarker and anti-viral drug targets | |
| JPH09507062A (ja) | 抗ｂ型肝炎ウイルスオリゴヌクレオチド | |
| JPWO2022204093A5 (enExample) | ||
| US20230265426A1 (en) | Combinatorial inhibition of mirnas for treatment of heart failure | |
| JPH07303485A (ja) | Ｈｃｖアンチセンスｒｎａ、それを含む発現ベクター、及び該ｒｎａ又は発現ベクターを含むｈｃｖ関連疾患治療剤 | |
| JP2008503569A5 (enExample) |